# Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

> **NCT05841849** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 1028 (estimated)

## Conditions studied

- Breast Cancer
- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Aprepitant
- **DRUG:** Palonosetron
- **DRUG:** Fosaprepitant

## Key facts

- **NCT ID:** NCT05841849
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07
- **Primary completion:** 2028-07
- **Final completion:** 2029-07
- **Target enrollment:** 1028 (ESTIMATED)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841849, "Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05841849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*